the aid library

Sort by:

Direction:

WHO Model Formulary for Children
recommended

World Health Organization WHO (2010) C_WHO

WHO Model Formulary for children based on the Second Model List of Essential Medicines for Children 2009. In 2007, the World Health Assembly passed a Resolution titled ‘Better Medicines for Children’. This resolution recognized the need for research and development into medicines for children,... more

Download (5254)

View PDF (2580)

Hepatology. A Clinical Textbook

Stefan Mauss, et al. Flying Publisher, Boehringer Ingelheim (2015)

Download (2327)

View PDF (1816)

Short Guide to Hepatitis C

Stefan Mauss, Thomas Berg, Jürgen Rockstroh et al. Flying Publisher (2014)

Exciting new treatment approaches make the management of hepatitic C one of the most rapidly developing areas of medicine. The Flying Publisher short Guide to Hepatitis C is an up-to-date source of information for physicians, residents and advanced medical students.

Download (174)

View PDF (773)

Alzheimer’s disease - Clinical Review

Burns, A. and S. Iliffe BMJ (2009) C2

BMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b158 (Published 05 February 2009) Cite this as: BMJ 2009;338:b158 Correspondence to: A Burns alistair.burns@manchester.ac.uk

Download (288)

View PDF (421)

The FORTA List “ Fit for The Aged“

Pazan, F.; C. Weiß and M. Wehling Universität Heidelberg (2018) C2

Expert Consensus Validation 2018. This innovative approach aimed at improving and facilitating the screening, prescribing and monitoring of drug therapy for older patients, is currently being further developed in the area of Clinical Pharmacology at the University of Heidelberg in Mannheim. This ap... more

Download (269)

View PDF (266)

Social Anxiety Disorder

National Institute for Health and Care Excellence (NICE) (2013) C2

Recognition, Assessment and Treatment National Clinical Guideline Number 159

Download (124)

View PDF (1375)

Treatment Gap for Anxiety Disorders is Global: Results of the World Mental Health Surveys in 21 countries

Alonso, J.; et al. (2018) CC

Depress Anxiety. 2018 March ; 35(3): 195–208. doi:10.1002/da.22711.

Download (628)

View PDF (540)

Depression: Powerpoint Presentation slides (mhGAP)
recommended

World Health Organization (WHO) (2015) C_WHO

Session outline •Introduction to depression •Assessment of depression •Management of depression •Follow-up •Review

Download (150)

View PDF (727)

Posttraumatic Stress Disorder in Children

Lubit, R.H. & Giardino, E.R. Medscape (2016) C1

Posttraumatic stress disorder (PTSD) in children and adolescents occurs as a result of a child’s exposure to one or more traumatic events: actual or threatened death, serious injury, or sexual violence. The victim may experience the event, witness it, learn about it from close family members or fr... more

Download (143)

View PDF (203)

Post Traumatic Stress Disorder in Children and Adolescents

Smita Srivastava Tufts Medical Center (2011) C1

Post-Traumatic Stress Disorder (PTSD) in children and adolescents occurs when a child is exposed to one or more events that are unexpected, uncontrollable, life-threatening, and likely to cause serious harm or injury to himself/herself or someone significantly important to the child. In response, th... more

Download (764)

View PDF (1614)

WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses

World Health Organization (2012)

The Access to Controlled Medications Programme identified the development of treatment guidelines that cover the treatment of all types of pain as one of the core areas of focus for improving access to opioid analgesics. Such guidelines are interesting both for health-care professionals and policy-... more

Download (1050)

View PDF (559)

Zambia Essential Medicines List (ZEML) 05
recommended

Ministry of Health, Zambia (2020) C1

2020 Version

Download (5545)

View PDF (425)

Zambia National Formulary 04
recommended

Ministry of Health, Zambia (2017) C1

Download (260)

View PDF (262)

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder
recommended

World Health Organization WHO (2015) C_WHO

Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment? The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm... more

Download (380)

View PDF (830)

Integrating palliative care and symptom relief into responses to humanitarian emergencies and crises: a WHO guide

World Health Organization WHO (2018) C_WHO

Humanitarian emergencies and crises (Humanitarian emergencies and crises) are large-scale events that may result in the breakdown of health care systems and society, forced displacement, death, and physical, psychological, social and spiritual suffering on a massive scale. Current responses to Human... more

Download (141)

View PDF (187)

Organizing and delivering services for child and adolescent mental health

C. Servili IACAPAP (2012) C2

Miscellaneous Chapter J.5

Download (614)

View PDF (1155)

Integrating palliative care and symptom relief into paediatrics: a WHO guide for health-care planners, implementers and managers

World Health Organization WHO (2018) C_WHO

People younger than 20 years comprise 35% of the global population and 40% of the global population of least-developed nations. The number of children - neonates, infants, children, and adolescents up to 19 years of age - who need pediatric palliative care (PPC) each year may be as high as 21 millio... more

Download (331)

View PDF (343)

WHO recommendations on adolescent health: guidelines approved by the WHO Guidelines Review Committee

World Health Organization (WHO) (2017) C_WHO

This document is meant to respond to the questions:
■ What health interventions should the adolescent receive and when should s/he receive it?
■ What health behaviours should the adolescent practise (or not practise)?

Download (284)

View PDF (185)

Integration of mental health and HIV interventions

World Health Organization WHO, UNICEF (2022) C_WHO

This joint publication by UNAIDS and WHO emphasizes the importance of integrating HIV prevention, testing, treatment and care and mental health services for people living with HIV. It provides a compilation of tools, best practices, recommendations and guidelines that facilitate the integration of i... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Model Formulary for Children recommended

Depression: Powerpoint Presentation slides (mhGAP) recommended

Zambia Essential Medicines List (ZEML) 05 recommended

Zambia National Formulary 04 recommended

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder recommended

WHO Model Formulary for Children
recommended

Depression: Powerpoint Presentation slides (mhGAP)
recommended

Zambia Essential Medicines List (ZEML) 05
recommended

Zambia National Formulary 04
recommended

Antidepressant medication in comparison with psychological treatment for moderate to severe depressive disorder
recommended